We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Calling all activists

15 May 2007 By Robert Cyran

The drug firm is paying 50% over its own market value for the German generic business just two years after it abandoned a smaller deal. Shareholders are unhappy. But it isn t putting the deal to a vote. If activists rally its disgruntled investors, Mylan may be sorry.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)